



## Clinical trial results:

### Matrix-associated autologous chondrocyte transplantation for grade four cartilage lesions of the knee joint - clinical and radiological outcome in correlation to the initial cell count of the chondrocyte graft

#### Summary

|                          |                |
|--------------------------|----------------|
| EudraCT number           | 2015-003584-11 |
| Trial protocol           | AT             |
| Global end of trial date | 12 May 2020    |

#### Results information

|                                |                  |
|--------------------------------|------------------|
| Result version number          | v1 (current)     |
| This version publication date  | 13 December 2021 |
| First version publication date | 13 December 2021 |

#### Trial information

##### Trial identification

|                       |               |
|-----------------------|---------------|
| Sponsor protocol code | MACT-IBK-2015 |
|-----------------------|---------------|

##### Additional study identifiers

|                                    |   |
|------------------------------------|---|
| ISRCTN number                      | - |
| ClinicalTrials.gov id (NCT number) | - |
| WHO universal trial number (UTN)   | - |

Notes:

#### Sponsors

|                              |   |
|------------------------------|---|
| Sponsor organisation name    | Medical University Innsbruck  |
| Sponsor organisation address | Christoph-Probst-Platz 1, Innrain 52, Innsbruck, Austria, 6020  |
| Public contact               | Dr. Eichinger Martin, Univ.-Klinik für Orthopädie und Traumatologie<br>Anichstraße 35<br>6020 Innsbruck, 0043 51250422821, martin.eichinger@tirol-kliniken.at |
| Scientific contact           | Dr. Eichinger Martin, Univ.-Klinik für Orthopädie und Traumatologie<br>Anichstraße 35<br>6020 Innsbruck, 0043 51250422821, martin.eichinger@tirol-kliniken.at |

Notes:

#### Paediatric regulatory details

|  |    |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP)       | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

## Results analysis stage

|  |             |
|--|-------------|
| Analysis stage                                       | Final       |
| Date of interim/final analysis                       | 12 May 2020 |
| Is this the analysis of the primary completion data? | Yes         |
| Primary completion date                              | 12 May 2016 |
| Global end of trial reached?                         | Yes         |
| Global end of trial date                             | 12 May 2020 |
| Was the trial ended prematurely?                     | No          |

Notes:

## General information about the trial

Main objective of the trial:

The objective of this study is to evaluate the clinical and radiological outcome (MRT) after MACT and to correlate these findings with the initial cell count of the chondrocyte graft. What is more, further knowledge about additional factors influencing the outcome of the surgery may be gained. This pilot study could provide valuable data for the design of a prospective randomized clinical trial.

Protection of trial subjects:

Die Magnetresonanztomographie (MRT) des Kniegelenkes entspricht der auch routinemäßig angewendeten MRT-Untersuchung. Bei dieser Untersuchung werden in den im Magnetfeld liegenden Körper (mindestens 1.5 Tesla) Radiowellen mit einer Frequenz von ca. 63.5 MHz gesendet. Schädliche Auswirkungen auf den menschlichen Körper sind bisher nicht bekannt geworden und aufgrund der geringen Energie der Radiowellen auch nicht anzunehmen.

Background therapy:

Bei dieser Patientenpopulation ist keine Dauerbehandlung/Dauermedikation vorgesehen.

Evidence for comparator:

Es gibt für diese Fragestellung keinen Komparator.

|   |                 |
|---|-----------------|
| Actual start date of recruitment                          | 01 October 2015 |
| Long term follow-up planned                               | No              |
| Independent data monitoring committee (IDMC) involvement? | No              |

Notes:

## Population of trial subjects

### Subjects enrolled per country

|                                      |             |
|--------------------------------------|-------------|
| Country: Number of subjects enrolled | Austria: 28 |
| Worldwide total number of subjects   | 28          |
| EEA total number of subjects         | 28          |

Notes:

### Subjects enrolled per age group

|   |   |
|---|---|
| In utero                                  | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days)                      | 0 |
| Infants and toddlers (28 days-23          | 0 |

|                           |    |
|---------------------------|----|
| months)                   |    |
| Children (2-11 years)     | 0  |
| Adolescents (12-17 years) | 0  |
| Adults (18-64 years)      | 28 |
| From 65 to 84 years       | 0  |
| 85 years and over         | 0  |

## Subject disposition

### Recruitment

Recruitment details:

In der Universitätsklinik für Unfallchirurgie wurden seit 2006, 64 Patienten mittels MACT behandelt und entsprechend einem standardisierten Protokoll nachbehandelt. Aus diesem Patientenkollektiv wurden retrospektiv alle Patienten, die den Einschlusskriterien entsprechen, ausgewählt.

### Pre-assignment

Screening details:

Von den 64 Patienten wurden 42 Patienten gescreent, wovon letztendlich 28 Patienten in die Studie eingeschlossen werden konnten.

### Period 1

|                              |                             |
|------------------------------|-----------------------------|
| Period 1 title               | Behandlung (overall period) |
| Is this the baseline period? | Yes                         |
| Allocation method            | Not applicable              |
| Blinding used                | Not blinded                 |

### Arms

|           |                |
|-----------|----------------|
| Arm title | Behandlungsarm |
|-----------|----------------|

Arm description:

Inhalt dieser Studie ist die Beurteilung der Gelenksfläche nach matrix-assoziiierter Chondrozytentransplantation mittels Magnetresonanztomographie sowie die Erhebung von klinischen Daten mittels einer Routineuntersuchung und mittels Patienten-Fragebögen.

|  |   |
|--|---|
| Arm type                               | Experimental  |
| Investigational medicinal product name | ATMP-Matrix associated autologous chondrocyte transplantation |
| Investigational medicinal product code |   |
| Other name                             |   |
| Pharmaceutical forms                   | Implantation matrix   |
| Routes of administration               | Implantation  |

Dosage and administration details:

Das ATMP wurde einmalig während der chirurgischen Versorgung implantiert.

| Number of subjects in period 1 | Behandlungsarm |
|--------------------------------|----------------|
| Started                        | 28             |
| Completed                      | 27             |
| Not completed                  | 1              |
| Consent withdrawn by subject   | 1              |

## Baseline characteristics

### Reporting groups

Reporting group title

Behandlung

Reporting group description: -

| Reporting group values                                | Behandlung | Total |  |
|---|------------|-------|--|
| Number of subjects                                    | 28         | 28    |  |
| Age categorical                                       |            |       |  |
| Units: Subjects                                       |            |       |  |
| In utero  | 0          | 0     |  |
| Preterm newborn infants<br>(gestational age < 37 wks) | 0          | 0     |  |
| Newborns (0-27 days)                                  | 0          | 0     |  |
| Infants and toddlers (28 days-23<br>months)           | 0          | 0     |  |
| Children (2-11 years)                                 | 0          | 0     |  |
| Adolescents (12-17 years)                             | 0          | 0     |  |
| Adults (18-64 years)                                  | 28         | 28    |  |
| From 65-84 years                                      | 0          | 0     |  |
| 85 years and over                                     | 0          | 0     |  |
| Age continuous  |            |       |  |
| Units: years  |            |       |  |
| arithmetic mean                                       | 38         |       |  |
| standard deviation                                    | ± 11       | -     |  |
| Gender categorical                                    |            |       |  |
| Units: Subjects                                       |            |       |  |
| Female  | 8          | 8     |  |
| Male  | 20         | 20    |  |

## End points

### End points reporting groups

|   |                |
|---|----------------|
| Reporting group title   | Behandlungsarm |
| Reporting group description:<br>Inhalt dieser Studie ist die Beurteilung der Gelenksfläche nach matrix-assoziierten Chondrozytentransplantation mittels Magnetresonanztomographie sowie die Erhebung von klinischen Daten mittels einer Routineuntersuchung und mittels Patienten-Fragebögen. |                |

### Primary: Radiologisches outcome: Defektfüllung

|                        |  |
|------------------------|--|
| End point title        | Radiologisches outcome: Defektfüllung <sup>[1]</sup> |
| End point description: |  |

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Tag 1 (MRT Untersuchung)

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Statistische Analysen wurden auf Grund der geringen Datenmenge nicht durchgeführt.

| End point values            | Behandlungsarm  |  |  |  |
|-----------------------------|-----------------|--|--|--|
| Subject group type          | Reporting group |  |  |  |
| Number of subjects analysed | 27              |  |  |  |
| Units: number               |                 |  |  |  |
| number (not applicable)     |                 |  |  |  |
| Komplette Füllung           | 23              |  |  |  |
| Inkomplette Füllung         | 4               |  |  |  |

### Statistical analyses

No statistical analyses for this end point

### Primary: Radiologisches outcome: Signalintensität des Ersatzgewebes bei Dual T2-FSE

|                        |   |
|------------------------|---|
| End point title        | Radiologisches outcome: Signalintensität des Ersatzgewebes bei Dual T2-FSE <sup>[2]</sup> |
| End point description: |   |

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Tag 1 (MRT Untersuchung)

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Statistische Analysen wurden auf Grund der geringen Datenmenge nicht durchgeführt.

| End point values            | Behandlungsarm  |  |  |  |
|-----------------------------|-----------------|--|--|--|
| Subject group type          | Reporting group |  |  |  |
| Number of subjects analysed | 27              |  |  |  |
| Units: number               |                 |  |  |  |
| number (not applicable)     |                 |  |  |  |
| Isointens                   | 16              |  |  |  |
| Moderat hyperintens         | 8               |  |  |  |
| Nicht beurteilbar           | 1               |  |  |  |
| Nicht beurteilt             | 2               |  |  |  |

### Statistical analyses

No statistical analyses for this end point

### Primary: Radiologisches outcome: Erguss

|                 |   |
|-----------------|---|
| End point title | Radiologisches outcome: Erguss <sup>[3]</sup> |
|-----------------|---|

End point description:

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Tag 1 (MRT Untersuchung)

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Statistische Analysen wurden auf Grund der geringen Datenmenge nicht durchgeführt.

| End point values            | Behandlungsarm  |  |  |  |
|-----------------------------|-----------------|--|--|--|
| Subject group type          | Reporting group |  |  |  |
| Number of subjects analysed | 27              |  |  |  |
| Units: Number               |                 |  |  |  |
| number (not applicable)     |                 |  |  |  |
| Erguss                      | 5               |  |  |  |
| Kein Erguss                 | 19              |  |  |  |
| Nicht beurteilbar           | 1               |  |  |  |
| Nicht beurteilt             | 2               |  |  |  |

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information<sup>[1]</sup>

Timeframe for reporting adverse events:

Tag 1 der Untersuchung

|                 |            |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

### Dictionary used

|                 |       |
|-----------------|-------|
| Dictionary name | CTCAE |
|-----------------|-------|

|                    |     |
|--------------------|-----|
| Dictionary version | 4.3 |
|--------------------|-----|

### Reporting groups

|                       |                |
|-----------------------|----------------|
| Reporting group title | Behandlungsarm |
|-----------------------|----------------|

Reporting group description:

Inhalt dieser Studie ist die Beurteilung der Gelenksfläche nach matrix-assoziierten Chondrozytentransplantation mittels Magnetresonanztomographie sowie die Erhebung von klinischen Daten mittels einer Routineuntersuchung und mittels Patienten-Fragebögen.

| Serious adverse events                            | Behandlungsarm |  |  |
|---|----------------|--|--|
| Total subjects affected by serious adverse events |                |  |  |
| subjects affected / exposed                       | 0 / 27 (0.00%) |  |  |
| number of deaths (all causes)                     | 0              |  |  |
| number of deaths resulting from adverse events    | 0              |  |  |

Frequency threshold for reporting non-serious adverse events: 5 %

| Non-serious adverse events                            | Behandlungsarm |  |  |
|---|----------------|--|--|
| Total subjects affected by non-serious adverse events |                |  |  |
| subjects affected / exposed                           | 0 / 27 (0.00%) |  |  |

Notes:

[1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.

Justification: Im Rahmen der einmaligen Studienvisite sind keine Adverse Events aufgetreten.



## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported